Ocera Therapeutics has completed enrollment for its Phase IIb ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy). Data is expected mid-2010. AST-120 absorbs ammonia and other gut derived toxins that are factors in the underlying cause of mild hepatic encephalopathy (MHE), a neurocognitive disorder present in a majority of patients with cirrhosis of the liver. Because MHE leads to a change in cognitive function including personality changes and intellectual impairment, the disorder ha...